October 1, 1998Shock

Randomized, Blinded, Placebo-Controlled Trial of Tissue Factor Pathway Inhibitor in Porcine Septic Shock

View Full Paper

Ask AI

Bookmark

Why the study?

Does tissue factor pathway inhibitor (TFPI) improve mortality and morbidity in a porcine model of septic shock?

Structured PICO

Does tissue factor pathway inhibitor (TFPI) improve mortality and morbidity in a porcine model of septic shock?

Population

32 pigs with peritonitis-induced bacteremia (Escherichia coli 0111.B4) producing septic shock, chronically instrumented with intracardiac transducers.

Intervention

Purified, reconstituted tissue factor pathway inhibitor (TFPI) (1 mg/kg bolus, 10 mg/kg/min for 48 h) administered immediately after E. coli implantation.

Comparator

Placebo (arginine buffer) or saline (combined into a control group, N=20).

Outcome

Mortality and morbidity.hard clinical

In a porcine model of septic shock, TFPI attenuated inflammatory cytokine responses but did not significantly improve survival.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

TFPI does not improve survival in this porcine septic shock model; leaves open whether cytokine attenuation warrants human translation studies.

Cite This Study

Goldfarb et al. (1998) studied this question.

synapsesocial.com/papers/6a89b8b375060194fdc98702 https://doi.org/10.1097/00024382-199810000-00005

View Full Paper

Ask AI

Bookmark

Implication

TFPI does not improve survival in this porcine septic shock model; leaves open whether cytokine attenuation warrants human translation studies.

Randomized, Blinded, Placebo-Controlled Trial of Tissue Factor Pathway Inhibitor in Porcine Septic Shock

Structured PICO

Discussion

Implication

Cite This Study

Randomized, Blinded, Placebo-Controlled Trial of Tissue Factor Pathway Inhibitor in Porcine Septic Shock

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider